These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3121396)

  • 41. Comparison between flare up and down regulation effects of luteinizing hormone-releasing hormone agonists in an in vitro fertilization program.
    Frydman R; Belaisch-Allart J; Parneix I; Forman R; Hazout A; Testart J
    Fertil Steril; 1988 Sep; 50(3):471-5. PubMed ID: 2970407
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ovarian response to human menopausal gonadotropin after therapy with the gonadotropin-releasing hormone agonist leuprolide.
    Nader S; Berkowitz AS; Winkel CA
    Am J Obstet Gynecol; 1988 Feb; 158(2):403-4. PubMed ID: 3124624
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cessation of low-dose gonadotropin releasing hormone agonist therapy followed by high-dose gonadotropin stimulation yields a favorable ovarian response in poor responders.
    Wang PT; Lee RK; Su JT; Hou JW; Lin MH; Hu YM
    J Assist Reprod Genet; 2002 Jan; 19(1):1-6. PubMed ID: 11893009
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Midcycle administration of single-dose GnRHa for luteal phase failure in women with ovarian hyperstimulation. A report of five cases.
    Wu TC
    J Reprod Med; 2000 Feb; 45(2):156-8. PubMed ID: 10710751
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Titrating luteinizing hormone surge requirements for ovulatory changes in primate follicles. I. Oocyte maturation and corpus luteum function.
    Zelinski-Wooten MB; Lanzendorf SE; Wolf DP; Chandrasekher YA; Stouffer RL
    J Clin Endocrinol Metab; 1991 Sep; 73(3):577-83. PubMed ID: 1908481
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adjunctive leuprolide therapy does not improve cycle fecundity in controlled ovarian hyperstimulation and intrauterine insemination of subfertile women.
    Dodson WC; Walmer DK; Hughes CL; Yancy SE; Haney AF
    Obstet Gynecol; 1991 Aug; 78(2):187-90. PubMed ID: 1906152
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Progesterone response to exogenous gonadotropins after suppression with leuprolide acetate in gamete intrafallopian transfer.
    Riemann DC; Schoolcraft WB; Sinton EB
    J Reprod Med; 1991 Mar; 36(3):190-4. PubMed ID: 1903164
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The treatment of patients with polycystic ovaries undergoing IVF.
    Franks S
    J Assist Reprod Genet; 1997 Jan; 14(1):12-4. PubMed ID: 9013303
    [No Abstract]   [Full Text] [Related]  

  • 49. Early follicular rise of serum progesterone concentration in response to a flare-up effect of gonadotrophin-releasing hormone agonist impairs follicular recruitment for in-vitro fertilization.
    Sims JA; Seltman HJ; Muasher SJ
    Hum Reprod; 1994 Feb; 9(2):235-40. PubMed ID: 8027278
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon).
    de Jong D; Macklon NS; Eijkemans MJ; Mannaerts BM; Coelingh Bennink HJ; Fauser BC;
    Fertil Steril; 2001 Apr; 75(4):688-93. PubMed ID: 11287020
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Follicular and luteal phase characteristics following early cessation of gonadotrophin-releasing hormone agonist during ovarian stimulation for in-vitro fertilization.
    Beckers NG; Laven JS; Eijkemans MJ; Fauser BC
    Hum Reprod; 2000 Jan; 15(1):43-9. PubMed ID: 10611186
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Endocrine composition of follicular fluid comparing human chorionic gonadotrophin to a gonadotrophin-releasing hormone agonist for ovulation induction.
    Yding Andersen C; Westergaard LG; Figenschau Y; Bertheussen K; Forsdahl F
    Hum Reprod; 1993 Jun; 8(6):840-3. PubMed ID: 8345072
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
    Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
    Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pure and highly purified follicle-stimulating hormone alone or in combination with human menopausal gonadotrophin for ovarian stimulation after pituitary suppression in in-vitro fertilization.
    Balasch J; Fábregues F; Creus M; Moreno V; Puerto B; Peñarrubia J; Carmona F; Vanrell JA
    Hum Reprod; 1996 Nov; 11(11):2400-4. PubMed ID: 8981119
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of clomiphene citrate on follicular and luteal phase luteinizing hormone concentrations in in vitro fertilization cycles stimulated with gonadotropins and gonadotropin-releasing hormone antagonist.
    Tavaniotou A; Albano C; Smitz J; Devroey P
    Fertil Steril; 2002 Apr; 77(4):733-7. PubMed ID: 11937125
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
    Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Concomitant gonadotropin-releasing hormone agonist and menotropin treatment for the synchronized induction of multiple follicles.
    Palermo R; Amodeo G; Navot D; Rosenwaks Z; Cittadini E
    Fertil Steril; 1988 Feb; 49(2):290-5. PubMed ID: 3123277
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Implantation and pregnancy rates in relation to oestradiol and progesterone profiles in cycles with and without the use of gonadotrophin-releasing hormone agonist suppression.
    Hassiakos D; Toner JP; Muasher SJ; Jones HW
    Hum Reprod; 1990 Nov; 5(8):1004-8. PubMed ID: 2127937
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Induction of ovulation with luprolide acetate and human menopausal gonadotropin.
    Lewinthal D; Taylor PJ; Pattinson HA; Corenblum B
    Fertil Steril; 1988 Apr; 49(4):585-8. PubMed ID: 3127242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.